Cerenome, Inc. (formerly Plus Therapeutics, Inc., rebranded August 2026, Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The company's CNSide Diagnostics platform, operated through its wholly-owned subsidiary CNSide Diagnostics LLC, supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through proprietary cerebrospinal fluid-based laboratory-developed tests. Its lead therapeutic candidate, REYOBIQ (rhenium Re186 obisbemeda), is a novel injectable radiotherapy being evaluated in three clinical trials: ReSPECT-GBM for recurrent glioblastoma (supported by NIH/NCI), ReSPECT-LM for leptomeningeal metastases (funded by a $17.6 million CPRIT grant), and ReSPECT-PBC for pediatric brain cancer (supported by a $3 million Department of Defense grant). The company generates revenue primarily through CPRIT grant funding and is in the early stages of commercializing its CNSide diagnostic tests. Cerenome operates a CAP-accredited CLIA laboratory and is building data and AI infrastructure to integrate diagnostic, molecular, imaging, and clinical datasets across its platform. Updated
CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin glioblastoma story. But here’s what you should actually be watching. Holders captured the move;…
Cerenome, Inc. (formerly Plus Therapeutics, Inc., rebranded August 2026, Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers.
